A dual Keap1 and p47phox inhibitor Ginsenoside Rb1 ameliorates high glucose/ox-LDL-induced endothelial cell injury and atherosclerosis
Abstract Oxidative stress is a vital contributor to the development and progression of diabetes-accelerated atherosclerosis. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a well-known molecule that participates in cellular defense against oxidative stress. Utilizing luciferase reporter assay...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2022-09-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-022-05274-x |
| _version_ | 1811201150764974080 |
|---|---|
| author | Zi-Chao Wang Kai-Ming Niu Yu-Jie Wu Kai-Rui Du Lian-Wen Qi Ye-Bo Zhou Hai-Jian Sun |
| author_facet | Zi-Chao Wang Kai-Ming Niu Yu-Jie Wu Kai-Rui Du Lian-Wen Qi Ye-Bo Zhou Hai-Jian Sun |
| author_sort | Zi-Chao Wang |
| collection | DOAJ |
| description | Abstract Oxidative stress is a vital contributor to the development and progression of diabetes-accelerated atherosclerosis. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a well-known molecule that participates in cellular defense against oxidative stress. Utilizing luciferase reporter assay from 379 natural products, we reported here that Ginsenoside Rb1 played a dual role in inhibiting Kelch-like ECH-associated protein 1 (Keap1) and p47phox luciferase reporter activities. In endothelial cells (ECs), Rb1 pretreatment enhanced cell viability, reduced oxidative stress, inflammation, endothelial-mesenchymal transition (EndMT), and apoptosis, as well as ameliorated mitochondrial quality following oxidized low-density lipoprotein (ox-LDL) plus high glucose (HG) challenge. Rb1 directly bound to Keap1 and promoted its ubiquitination and proteasomal degradation dependent on lysine residues (K108, K323, and K551) by recruiting the E3 ligase synovial apoptosis inhibitor 1 (SYVN1), leading to Nrf2 dissociation from Keap1, Nrf2 nuclear translocation, Nrf2/PGC-1α complex formation. We further identified that Rb1 could bind to p47phox and reduce its phosphorylation and membrane translocation, thereby disrupting the assembly of the NOX2 complex. Importantly, Rb1-mediated preservation of cytoplasmic p47phox stabilized and contributed to Nrf2 activation. Additionally, we revealed that Rb1 reduced aortic atherosclerotic plaque formation along with reductions in oxidative stress and inflammatory response in streptozotocin (STZ)-induced ApoE−/− mice, but not in ApoE−/− mice with deficiency of Nrf2 and PGC-1α. Collectively, we demonstrated that Rb1, which directly targeted Keap1 and p47phox in ECs, may be an attractive candidate for the treatment of atherosclerosis in diabetes. |
| first_indexed | 2024-04-12T02:15:59Z |
| format | Article |
| id | doaj.art-b1aba21faf484ff3b46c70e7cc550bb0 |
| institution | Directory Open Access Journal |
| issn | 2041-4889 |
| language | English |
| last_indexed | 2024-04-12T02:15:59Z |
| publishDate | 2022-09-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Cell Death and Disease |
| spelling | doaj.art-b1aba21faf484ff3b46c70e7cc550bb02022-12-22T03:52:15ZengNature Publishing GroupCell Death and Disease2041-48892022-09-0113911510.1038/s41419-022-05274-xA dual Keap1 and p47phox inhibitor Ginsenoside Rb1 ameliorates high glucose/ox-LDL-induced endothelial cell injury and atherosclerosisZi-Chao Wang0Kai-Ming Niu1Yu-Jie Wu2Kai-Rui Du3Lian-Wen Qi4Ye-Bo Zhou5Hai-Jian Sun6State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical UniversityState Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical UniversityState Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical UniversityState Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical UniversityState Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical UniversityDepartment of Physiology, Nanjing Medical UniversityState Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical UniversityAbstract Oxidative stress is a vital contributor to the development and progression of diabetes-accelerated atherosclerosis. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a well-known molecule that participates in cellular defense against oxidative stress. Utilizing luciferase reporter assay from 379 natural products, we reported here that Ginsenoside Rb1 played a dual role in inhibiting Kelch-like ECH-associated protein 1 (Keap1) and p47phox luciferase reporter activities. In endothelial cells (ECs), Rb1 pretreatment enhanced cell viability, reduced oxidative stress, inflammation, endothelial-mesenchymal transition (EndMT), and apoptosis, as well as ameliorated mitochondrial quality following oxidized low-density lipoprotein (ox-LDL) plus high glucose (HG) challenge. Rb1 directly bound to Keap1 and promoted its ubiquitination and proteasomal degradation dependent on lysine residues (K108, K323, and K551) by recruiting the E3 ligase synovial apoptosis inhibitor 1 (SYVN1), leading to Nrf2 dissociation from Keap1, Nrf2 nuclear translocation, Nrf2/PGC-1α complex formation. We further identified that Rb1 could bind to p47phox and reduce its phosphorylation and membrane translocation, thereby disrupting the assembly of the NOX2 complex. Importantly, Rb1-mediated preservation of cytoplasmic p47phox stabilized and contributed to Nrf2 activation. Additionally, we revealed that Rb1 reduced aortic atherosclerotic plaque formation along with reductions in oxidative stress and inflammatory response in streptozotocin (STZ)-induced ApoE−/− mice, but not in ApoE−/− mice with deficiency of Nrf2 and PGC-1α. Collectively, we demonstrated that Rb1, which directly targeted Keap1 and p47phox in ECs, may be an attractive candidate for the treatment of atherosclerosis in diabetes.https://doi.org/10.1038/s41419-022-05274-x |
| spellingShingle | Zi-Chao Wang Kai-Ming Niu Yu-Jie Wu Kai-Rui Du Lian-Wen Qi Ye-Bo Zhou Hai-Jian Sun A dual Keap1 and p47phox inhibitor Ginsenoside Rb1 ameliorates high glucose/ox-LDL-induced endothelial cell injury and atherosclerosis Cell Death and Disease |
| title | A dual Keap1 and p47phox inhibitor Ginsenoside Rb1 ameliorates high glucose/ox-LDL-induced endothelial cell injury and atherosclerosis |
| title_full | A dual Keap1 and p47phox inhibitor Ginsenoside Rb1 ameliorates high glucose/ox-LDL-induced endothelial cell injury and atherosclerosis |
| title_fullStr | A dual Keap1 and p47phox inhibitor Ginsenoside Rb1 ameliorates high glucose/ox-LDL-induced endothelial cell injury and atherosclerosis |
| title_full_unstemmed | A dual Keap1 and p47phox inhibitor Ginsenoside Rb1 ameliorates high glucose/ox-LDL-induced endothelial cell injury and atherosclerosis |
| title_short | A dual Keap1 and p47phox inhibitor Ginsenoside Rb1 ameliorates high glucose/ox-LDL-induced endothelial cell injury and atherosclerosis |
| title_sort | dual keap1 and p47phox inhibitor ginsenoside rb1 ameliorates high glucose ox ldl induced endothelial cell injury and atherosclerosis |
| url | https://doi.org/10.1038/s41419-022-05274-x |
| work_keys_str_mv | AT zichaowang adualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT kaimingniu adualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT yujiewu adualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT kairuidu adualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT lianwenqi adualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT yebozhou adualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT haijiansun adualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT zichaowang dualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT kaimingniu dualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT yujiewu dualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT kairuidu dualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT lianwenqi dualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT yebozhou dualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis AT haijiansun dualkeap1andp47phoxinhibitorginsenosiderb1ameliorateshighglucoseoxldlinducedendothelialcellinjuryandatherosclerosis |